{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T16:14:14Z","timestamp":1791044054256,"version":"4.1.0"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofsurgicalresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Surgical Research"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.jss.2022.04.005","type":"journal-article","created":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T13:53:00Z","timestamp":1651067580000},"page":"131-137","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Expression of PD-L1 in Patients With Malignant Peritoneal Mesothelioma: A Pilot Study"],"prefix":"10.1016","volume":"277","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2923-6573","authenticated-orcid":false,"given":"Victor P.","family":"Gazivoda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1264-2054","authenticated-orcid":false,"given":"Aaron W.","family":"Kangas-Dick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2523-2919","authenticated-orcid":false,"given":"Alissa A.","family":"Greenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Roshal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunxia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3788-050X","authenticated-orcid":false,"given":"Dirk F.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0250-120X","authenticated-orcid":false,"given":"Russell C.","family":"Langan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy J.","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Minerowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Richard","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jss.2022.04.005_bib1","doi-asserted-by":"crossref","first-page":"05","DOI":"10.30699\/acadpub.mci.3.3.5","article-title":"Current concepts in the diagnosis and management of patients with malignant peritoneal mesothelioma","volume":"03","author":"Ginalis","year":"2019","journal-title":"Multidiscip Cancer Invest"},{"key":"10.1016\/j.jss.2022.04.005_bib2","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1245\/s10434-014-3978-x","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis","volume":"22","author":"Helm","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jss.2022.04.005_bib3","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S2213-2600(18)30151-6","article-title":"Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study","volume":"6","author":"Calabr\u00f2","year":"2018","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jss.2022.04.005_bib4","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jamaoncol.2018.5428","article-title":"Efficacy and safety of avelumab treatment in patients with advanced unresectable mesothelioma","volume":"5","author":"Hassan","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jss.2022.04.005_bib5","doi-asserted-by":"crossref","first-page":"8565","DOI":"10.1200\/JCO.2018.36.15_suppl.8565","article-title":"Phase II trial of pembrolizumab (P) in patients (pts) with previously treated mesothelioma (MM)","volume":"36","author":"Desai","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jss.2022.04.005_bib6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.humpath.2019.02.001","article-title":"Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays","volume":"87","author":"Chapel","year":"2019","journal-title":"Hum Pathol"},{"key":"10.1016\/j.jss.2022.04.005_bib7","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/s41416-020-01130-x","article-title":"Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy","volume":"124","author":"White","year":"2021","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jss.2022.04.005_bib8","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1136\/jclinpath-2020-206832","article-title":"PD-L1 expression by Tumor Proportion Score (TPS) and Combined Positive Score (CPS) are similar in non-small cell lung cancer (NSCLC)","volume":"74","author":"de Marchi","year":"2021","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.jss.2022.04.005_bib9","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.ejso.2017.05.009","article-title":"Immunohistochemical evaluation of two antibodies against PD-L1 and prognostic significance of PD-L1 expression in epithelioid peritoneal malignant mesothelioma: a RENAPE study","volume":"43","author":"Valmary-Degano","year":"2017","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.jss.2022.04.005_bib10","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/j.jtho.2016.07.033","article-title":"Malignant mesothelioma effusions are infiltrated by CD3 + T cells highly expressing PD-L1 and the PD-L1 + tumor cells within these effusions are susceptible to ADCC by the anti\u2013PD-L1 antibody avelumab","volume":"11","author":"Khanna","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jss.2022.04.005_bib11","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1038\/s41416-020-01214-8","article-title":"Comment on \u201cHeterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy\u201d","volume":"124","author":"Yang","year":"2020","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jss.2022.04.005_bib12","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/s41416-020-01215-7","article-title":"Response to comment on \u201cHeterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy\u201d","volume":"124","author":"White","year":"2020","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jss.2022.04.005_bib13","doi-asserted-by":"crossref","first-page":"e564","DOI":"10.1016\/j.cllc.2019.04.010","article-title":"Shorter survival in malignant pleural mesothelioma patients with high PD-L1 expression associated with sarcomatoid or biphasic histology subtype: a series of 214 cases from the bio-MAPS cohort","volume":"20","author":"Brosseau","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jss.2022.04.005_bib14","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.jss.2022.04.005_bib15","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.3389\/fimmu.2017.01830","article-title":"Tertiary lymphoid structures in cancer: drivers of antitumor immunity, immunosuppression, or bystander sentinels in disease?","volume":"8","author":"Colbeck","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.jss.2022.04.005_bib16","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41568-019-0144-6","article-title":"Tertiary lymphoid structures in the era of cancer immunotherapy","volume":"19","author":"Saut\u00e8s-Fridman","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jss.2022.04.005_bib17","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/s41423-020-00565-9","article-title":"Tumor-infiltrating lymphocytes in the immunotherapy era","volume":"18","author":"Paijens","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.jss.2022.04.005_bib18","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1038\/s41467-019-09307-6","article-title":"Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications","volume":"10","author":"Blum","year":"2019","journal-title":"Nat Commun"}],"container-title":["Journal of Surgical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022480422001871?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022480422001871?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T14:58:14Z","timestamp":1758380294000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022480422001871"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":18,"alternative-id":["S0022480422001871"],"URL":"https:\/\/doi.org\/10.1016\/j.jss.2022.04.005","relation":{},"ISSN":["0022-4804"],"issn-type":[{"value":"0022-4804","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expression of PD-L1 in Patients With Malignant Peritoneal Mesothelioma: A Pilot Study","name":"articletitle","label":"Article Title"},{"value":"Journal of Surgical Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jss.2022.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}